Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates

Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates

US Patent 10363317 · Granted Jul 30, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors2025
Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation 2025
Use of a combination of Dbait molecule and PARP inhibitors to treat cancer2021
Treatment of cancer by systemic administration of Dbait molecules2020
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2020
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2020
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2020
Use of a combination of Dbait molecule and PARP inhibitors to treat cancer2020
Substituted 2-aminopyridine protein kinase inhibitor2017
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2017
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2017
Optimized in vivo delivery system with endosomolytic agents for nucleic acid con2017